United Therapeutics (UTHR) Depreciation & Amortization (CF) (2009 - 2026)

United Therapeutics has disclosed Depreciation & Amortization (CF) across 18 years of filings, most recently posting $24.2 million for Q2 2026.

• In Q2 2026, Depreciation & Amortization (CF) rose 14.69% year-over-year to $24.2 million; the TTM figure through Jun 2026 stood at $91.5 million (up 14.81% YoY), while the FY2025 annual figure was $85.6 million, up 18.07% from the prior year.
• Depreciation & Amortization (CF) came in at $24.2 million for Q2 2026 at United Therapeutics, up from $22.6 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $24.2 million in Q2 2026 to a low of $12.5 million in Q1 2022.
• Average Depreciation & Amortization (CF) over 5 years is $17.2 million, with a median of $16.8 million recorded in 2024.
• Year-over-year, Depreciation & Amortization (CF) changed 0.0% in 2022 and surged 44.96% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $13.2 million in 2022, then gained by 3.79% to $13.7 million in 2023, then surged by 43.8% to $19.7 million in 2024, then rose by 15.74% to $22.8 million in 2025, then climbed by 6.14% to $24.2 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $24.2 million in Q2 2026, $22.6 million in Q1 2026, and $22.8 million in Q4 2025.